PMID- 36899299
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230314
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Mar 10
TI  - Prevalence and factors associated with reported adverse-events among patients on 
      multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda.
PG  - 149
LID - 10.1186/s12879-023-08085-3 [doi]
LID - 149
AB  - BACKGROUND: Multi-drug-resistant tuberculosis (MDR-TB) treatment involves toxic 
      drugs that cause adverse events (AEs), which are life-threatening and may lead to 
      death if not well managed. In Uganda, the prevalence of MDR-TB is increasingly 
      high, and about 95% of the patients are on treatment. However, little is known 
      about the prevalence of AEs among patients on MDR-TB medicines. We therefore 
      estimated the prevalence of reported adverse events (AEs) of MDR-TB drugs and 
      factors associated with AEs in two health facilities in Uganda. METHODS: A 
      retrospective cohort study of MDR-TB was conducted among patients enrolled at 
      Mulago National Referral and Mbarara Regional Referral hospitals in Uganda. 
      Medical records of MDR-TB patients enrolled between January 2015 and December 
      2020 were reviewed. Data on AEs, which were defined as irritative reactions to 
      MDR-TB drugs, were extracted and analyzed. To describe reported AEs, descriptive 
      statistics were computed. A modified Poisson regression analysis was used to 
      determine factors associated with reported AEs. RESULTS: Overall, 369 (43.1%) of 
      856 patients had AEs, and 145 (17%) of 856 had more than one. Joint pain 
      (244/369, or 66%), hearing loss (75/369, or 20%), and vomiting (58/369, or 16%) 
      were the most frequently reported effects. Patients started on the 24-month 
      regimen (adj. PR = 1.4, 95%; 1.07, 1.76) and individualized regimens (adj. 
      PR = 1.5, 95%; 1.11, 1.93) were more likely to suffer from AEs. Lack of transport 
      for clinical monitoring (adj. PR = 1.9, 95%; 1.21, 3.11); alcohol consumption 
      (adj. PR = 1.2, 95%; 1.05, 1.43); and receipt of directly observed therapy from 
      peripheral health facilities (adj. PR = 1.6, 95%; 1.10, 2.41) were significantly 
      associated with experiencing AEs. However, patients who received food supplies 
      (adj. PR = 0.61, 95%; 0.51, 0.71) were less likely to suffer from AEs. 
      CONCLUSION: The frequency of adverse events reported by MDR-TB patients is 
      considerably high, with joint pain being the most common. Interventions such as 
      the provision of food supplies, transportation, and consistent counseling on 
      alcohol consumption to patients at initiation treatment facilities may contribute 
      to a reduction in the rate of occurrence of AEs.
CI  - (c) 2023. The Author(s).
FAU - Ategyeka, Paul Mukama
AU  - Ategyeka PM
AD  - College of Health Sciences School of Public Health, Makerere University, Kampala, 
      Uganda. paulategyekap@gmail.com.
FAU - Muhoozi, Michael
AU  - Muhoozi M
AD  - College of Health Sciences School of Public Health, Makerere University, Kampala, 
      Uganda.
AD  - Makerere University Center for Health and Population Research, Kampala, Uganda.
FAU - Naturinda, Racheal
AU  - Naturinda R
AD  - College of Health Sciences School of Public Health, Makerere University, Kampala, 
      Uganda.
FAU - Kageni, Peter
AU  - Kageni P
AD  - College of Health Sciences Department of Pharmacy, Makerere University, Kampala, 
      Uganda.
FAU - Namugenyi, Carol
AU  - Namugenyi C
AD  - Mulago National Referral Hospital TB ward 5 and 6, Kampala, Uganda.
FAU - Kasolo, Amos
AU  - Kasolo A
AD  - Mbarara Regional Referral Hospital TB ward, Mbarara, Uganda.
FAU - Kisaka, Stevens
AU  - Kisaka S
AD  - College of Health Sciences School of Public Health, Makerere University, Kampala, 
      Uganda.
AD  - College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere 
      University, Kampala, Uganda.
AD  - Center for Epidemiological Modelling and Analysis (CEMA), University of Nairobi 
      Institute of Tropical and Infectious Diseases, Nairobi, Kenya.
FAU - Kiwanuka, Noah
AU  - Kiwanuka N
AD  - College of Health Sciences School of Public Health, Makerere University, Kampala, 
      Uganda.
LA  - eng
PT  - Journal Article
DEP - 20230310
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
RN  - 0 (Antitubercular Agents)
SB  - IM
MH  - Humans
MH  - Antitubercular Agents/therapeutic use
MH  - Retrospective Studies
MH  - Uganda/epidemiology
MH  - Prevalence
MH  - *Tuberculosis, Multidrug-Resistant/drug therapy
MH  - *Tuberculosis/drug therapy
MH  - Hospitals
MH  - Referral and Consultation
PMC - PMC9999637
OTO - NOTNLM
OT  - Adverse-events
OT  - Multi-drug resistant
OT  - Tuberculosis
COIS- The authors declare that they have no competing interests.
EDAT- 2023/03/11 06:00
MHDA- 2023/03/15 06:00
PMCR- 2023/03/10
CRDT- 2023/03/10 23:32
PHST- 2022/10/24 00:00 [received]
PHST- 2023/02/15 00:00 [accepted]
PHST- 2023/03/10 23:32 [entrez]
PHST- 2023/03/11 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2023/03/10 00:00 [pmc-release]
AID - 10.1186/s12879-023-08085-3 [pii]
AID - 8085 [pii]
AID - 10.1186/s12879-023-08085-3 [doi]
PST - epublish
SO  - BMC Infect Dis. 2023 Mar 10;23(1):149. doi: 10.1186/s12879-023-08085-3.